TSXV:BTI.H - Post by User
Comment by
JDavenporton Apr 21, 2022 3:32pm
147 Views
Post# 34621540
RE:trying to understand?
RE:trying to understand?After more than 14 years in business, fuzzy, Bioasis needs to prove something. Companies entering collaborations mean one thing - the companies, as we, want to know if xB3 works and if it can be used to create something of therapeutic and commercial value.
So what comes first?
A deal and an IND submission seem to be good candidates. It's unlikely that that a collaborator can apply for IND approval for their own xB3-drug without a substantial agreement with Bioasis.
Bioasis, on the other hand, may be able to submit an IND application for one of its own drugs even though the preclinical work may have been done by another company like J&J/Janssen, Daiichi Sankyo/AZ or Protalix. But again, the partner may require a deal before Bioasis moves forward with anything.
Both a deal and an IND application indicate preclinical successes. IND approval, the approval to administer the drug to humans, would certainly make some news. Somewhere in these events we could see the share price rise.
I expect substantial deals out of this. We're talking about very valuable drugs that would lie dormant without a means of transporting them to the brain. The successful delivery of one drug increases confidence that xB3 can deliver almost any drug. So advancement of one drug implies increased value for all xB3 programs. It may be hard for the market to ignore that.
We need accomplishments, although the long list of partnerships could feed the share price once somebody accomplishes something.
Soon? Likely.
AIMNotVeryHO
jd